DK2817620T3 - System til immunterapi rettet mod tumorformering og -progression - Google Patents

System til immunterapi rettet mod tumorformering og -progression Download PDF

Info

Publication number
DK2817620T3
DK2817620T3 DK13709633.5T DK13709633T DK2817620T3 DK 2817620 T3 DK2817620 T3 DK 2817620T3 DK 13709633 T DK13709633 T DK 13709633T DK 2817620 T3 DK2817620 T3 DK 2817620T3
Authority
DK
Denmark
Prior art keywords
cells
cell
tumor
cancer
population
Prior art date
Application number
DK13709633.5T
Other languages
English (en)
Inventor
Nancy L Parenteau
Joseph C Laning
Janet H Young
Original Assignee
Verik Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verik Bio Inc filed Critical Verik Bio Inc
Application granted granted Critical
Publication of DK2817620T3 publication Critical patent/DK2817620T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)

Claims (15)

1. Fremgangsmåde til identificering af regenereringsdygtige (C-RC)-populationer af cancerceller hos et individ, omfattende (a) at dyrke en tumorprøve opnået fra et individ under betingelser, der inducerer en stressreaktion i differentierende og differentierede celler, men tillader C-RC-celler at formere sig, og som aktiverer en regenerativ reaktion; (b) at isolere den dominerende, aktivt ekspanderende, hurtigst delende population af celler fra trin (a); og (c) at dyrke cellerne til 60 til 95 % konfluens til opnåelse af en population på 51 % til 100 % C-RC, hvor celledyrkningsbetingelserne er udvalgt fra gruppen bestående af: (i) serumfrit, defineret celledyrkningsmedium, der inducerer apoptose og/eller nekrose af de differentierende og differentierede celler, (ii) medium indeholdende cAMP-forøgende midler og (iii) medium udformet til at inhibere eller bryde celle-celle-adhæsion.
2. Fremgangsmåde ifølge krav 1, hvor mediet, der inducerer apoptose og/eller nekrose af cellerne, omfatter et middel udvalgt fra gruppen bestående af tumornekrosefaktor-alfa (TNF-α), interleukin 1-beta og interferongamma (IFN-y).
3. Fremgangsmåde ifølge krav 1, hvor mediet udformet til at inhibere eller bryde celle-celle-adhæsion omfatter et middel udvalgt fra gruppen bestående af nitrogenoxid, hydrokolloid, dextran og mindre end ca. 1 mM calcium.
4. Fremgangsmåde ifølge krav 1, hvor den dyrkede tumorprøve er et tumor-eksplantat, idet fremgangsmåden yderligere omfatter at bekræfte C-RC-cellernes tumorformerende potentiale.
5. Fremgangsmåde ifølge krav 1, yderligere omfattende at dyrke de isolerede celler fra trin (a), hvor 80 % til 100 % af cellerne opnået fra trin (c) er C-RC-celler udvalgt fra gruppen bestående af VSEC-, SDEC- og SCEC-celler.
6. Fremgangsmåde til identificering af C-RC-celle-specifikke T-celler, omfattende at blande C-RC-celler isoleret i henhold til fremgangsmåden ifølge krav 1 med isolerede CD8+ T-celler fra normale donorer eller cancerdonorer, og at isolere T-celler, der reagerer med de behandlede C-RC-celler, hvor de reaktive T-celler omfatter T-celle-receptorer (TCR), der er rettet mod et C-RC-specifikt antigen.
7. Fremgangsmåde ifølge krav 6, omfattende (et) yderligere trin udvalgt fra gruppen bestående af; (i) at behandle C-RC-cellerne med en interferon-gamma-agonist til øgning af ekspression af HLA-peptid-komplekser; (ii) at tilsætte en in v/Yro-aktiveringsprotokol, der selekterer for CD8+ T-celler, der er reaktive over for passende præsenteret peptidantigen i forbindelse med patientrelevante HLA-molekyler; (iii) at isolere det C-RC-specifikke antigen; (iv) at isolere og sekventere det C-RC-specifikke antigen; (v) at isolere det C-RC-specifikke antigen og fremstille antistoffer eller molekylære sonder til det C-RC-specifikke antigen; (vi) at isolere det C-RC-specifikke antigen, at fordøje det C-RC-specifikke antigen til fremstilling af en flerhed af peptider og præsentere et eller flere af peptiderne for CD8+ T-celler og udvælge T-celler, der er reaktive over for det ene eller de flere af peptiderne; og (vii) at klone T-celle-receptorerne fra de reaktive T-celler til fremstilling af et klonet TCR-konstrukt.
8. Fremgangsmåde ifølge krav 7, omfattende at sammenligne det C-RC-specifikke antigen, eller antistoffer eller sonder dertil, med antigen fra ikke-tumorceller eller celler af forskellige typer af tumorer.
9. Fremgangsmåde ifølge krav 7, yderligere omfattende at transducere en population af T-celler med det klonede TCR-konstrukt og at teste de transdu-cerede T-celler for deres evne til at binde og reagere på eksprimeret HLA-begrænset peptidkompleks.
10. Isoleret tumor-C-RC-cellepopulation fremstillet ved fremgangsmåden ifølge krav 1.
11. Isoleret tumorantigen, der kan opnås ved fremgangsmåden ifølge krav 7.
12. Klonet TCR, der kan opnås ved fremgangsmåden ifølge krav 7.
13. T-celler til anvendelse ved behandling af cancer hos en patient, hvor T-cellerne er transduceret med en ekspressionsvektor, der koder for T-celle-receptorer, der er reaktive over for det ene eller de flere antigener, der er identificeret eller opnået ved at analysere en cancerbiopsi fra patienten til bestemmelse af forekomsten af et eller flere antigener identificeret under anvendelse af fremgangsmåden ifølge krav 9, hvor T-cellerne er opnået fra patienten eller fra en donor, inden transduktion.
14. T-celler til anvendelse ifølge krav 13, hvor patienten er identificeret som værende positiv for et eller flere antigener med tilsvarende HLA klasse I-begrænsning.
15. T-celler til anvendelse ifølge krav 13, hvor T-cellerne er transduceret til at eksprimere cytokin eller adjuvans til at øge T-celle-responset.
DK13709633.5T 2012-02-22 2013-02-22 System til immunterapi rettet mod tumorformering og -progression DK2817620T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601893P 2012-02-22 2012-02-22
PCT/US2013/027445 WO2013126785A1 (en) 2012-02-22 2013-02-22 A system for immunotherapy targeting tumor propagation and progression

Publications (1)

Publication Number Publication Date
DK2817620T3 true DK2817620T3 (da) 2016-09-05

Family

ID=47884527

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13709633.5T DK2817620T3 (da) 2012-02-22 2013-02-22 System til immunterapi rettet mod tumorformering og -progression

Country Status (4)

Country Link
US (3) US10247731B2 (da)
EP (1) EP2817620B1 (da)
DK (1) DK2817620T3 (da)
WO (1) WO2013126785A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10317402B2 (en) 2014-12-03 2019-06-11 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CA3130930A1 (en) * 2019-03-19 2020-09-24 Kyuson Yun Methods and systems for evaluation of cell samples
CN112649614A (zh) * 2020-12-09 2021-04-13 中国医学科学院肿瘤医院 Cd8+肿瘤浸润淋巴细胞作为标志物在食管小细胞癌预后判断中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
EP1629089A1 (en) 2003-06-03 2006-03-01 Organ Recovery Systems, Inc. Selection and propagation of progenitor cells
US20070244046A1 (en) * 2006-03-29 2007-10-18 Margarita Gutova Identification and characterization of cancer stem cells and methods of use
WO2009045201A1 (en) * 2006-08-02 2009-04-09 Biogen Idec Ma Inc. Cancer stem cells
US7781179B2 (en) * 2006-12-07 2010-08-24 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of transitional cell carcinoma stem cells
CA2675521C (en) * 2007-01-22 2016-04-26 Raven Biotechnologies Human cancer stem cells
EP2689787A1 (en) * 2010-09-03 2014-01-29 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
EP2772268B8 (en) * 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule

Also Published As

Publication number Publication date
US20180252719A1 (en) 2018-09-06
EP2817620A1 (en) 2014-12-31
US9977025B2 (en) 2018-05-22
EP2817620B1 (en) 2016-06-01
US10247731B2 (en) 2019-04-02
WO2013126785A1 (en) 2013-08-29
US20130273083A1 (en) 2013-10-17
US20160161488A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
Poropatich et al. OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity
Garbe et al. Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells
US12517112B2 (en) Immune cell organoid co-cultures
Li et al. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients
Le et al. Follicular B lymphomas generate regulatory T cells via the ICOS/ICOSL pathway and are susceptible to treatment by anti-ICOS/ICOSL therapy
Bukur et al. The role of classical and non-classical HLA class I antigens in human tumors
US20180252719A1 (en) System for immunotherapy targeting tumor propagation and progression
Asemissen et al. Identification of a highly immunogenic HLA-A* 01-binding T cell epitope of WT1
EP3374497B1 (en) Modified macrophages for use in the treatment of cancer
TWI733719B (zh) 改善的組合物及用於新表位之病毒遞送的方法及其應用
DuCote et al. EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas
Manfredonia et al. Maintenance of primary human colorectal cancer microenvironment using a perfusion bioreactor‐based 3D culture system
Goncharov et al. Pinpointing the tumor-specific T cells via TCR clusters
Hrbac et al. HLA-E and HLA-F are overexpressed in glioblastoma and HLA-E increased after exposure to ionizing radiation
CN110257478A (zh) 一种肿瘤个体化疫苗的有效新抗原肽的快速筛选方法
US20230052157A1 (en) Method for obtaining nucleic acid for sequencing
Liu et al. B7‑H4 expression in bladder urothelial carcinoma and immune escape mechanisms
Scheibenbogen et al. Identification of known and novel immunogenic T‐cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL‐2‐based treatment
Thier et al. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
Locke et al. Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma
Leko et al. Utilization of primary tumor samples for cancer neoantigen discovery
Akins et al. An engineered glioblastoma model yields macrophage-secreted drivers of invasion
CN108014327B (zh) 针对肿瘤相关巨噬细胞的肿瘤免疫治疗靶标
CN119372160A (zh) 源自ido1基因的hla-a*11:01肾细胞癌肿瘤抗原短肽
Tschiedel et al. Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia